本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
Beerfest Asia will also be launching overseas for the first time since the pandemic, partnering with Index Creative Village for Brewtopia Bangkok in November SINGAPORE, June 16, 2023 /PRNewswire/ -- New brews from award-winning institutions such as Moon Dog Craft Brewery in Australia, Young Master Brewery in Hong Kong, and Singapore's own Specific Gravity Beverage Company will be making their debut at Beerfest Asia from 22 – 25 June 2023 at Kallang Outdoor Arena (carpark outside Leisure Park Kallang). They are also among the 160 new beers launching in the Singapore market for the first time. Discover Over 600 Top-Selling Brews, Fresh New Flavours And Gourmet Delights Now in its 13th edition, Asia's largest beer festival will feature more than 600 varieties of beer as well as gourmet delights from a large roster of critically-acclaimed restaurants that include Meatsmith, Luke's Lobster, Chimichanga and Gyu-san. New beer highlights include the best of UK craft beers from Quality Drops and Beer Clan, as well as crowd favourites Smith Street Taps and Friends introducing fresh brews from award-winning Australian craft breweries. Visitors will also be able to sample winning brews from the Asia Beer Awards held at Beerfest Asia. The winners across 14 categories will be crowned at the awards ceremony on 22 June, selected via blind taste tests by an international panel of 15 brewers, BJCP-certified judges and cicerones. Beyond Beer – Explore A Wide Range of Seltzers, Wines And Spirits Those looking for healthier beer alternatives can sample from an exciting range of hard seltzers, with Ollie Hard Seltzer introducing their Beerfest exclusive Yuzu and Pandan flavours on tap, while Trouble Brewing will be bringing their new hard seltzers brewed from blue agave. Tiger Beer will also be offering their new Tiger Soju Infused Lager with flavours such as Gutsy Grape and Cheeky Plum. Beam Suntory, prestige tequila house Código 1530 and boutique flavoured vodka Clumzy Plumzy will be headlining the Spirits & Wine Lounge at Beerfest Asia. Expect four themed-nights of live music: After-work Chill Thursday, Retro Friday, Top Hits Saturday and Lunar Invasion Sunday. Check out the top 10 new launches and highlights at Beerfest Asia 2023 here. Rock And Party The Night Away Ramping up the live entertainment programme at Beerfest Asia will be popular tribute act The Australian AC/DC Experience and Singapore-based Pink Floyd tribute band Welcome To The Machine. They are among over 30 musical acts performing at three zones throughout the event. The four-day entertainment line-up will include an electrifying mix of international & local tribute bands, popular homegrown musicians, stalwarts of the local underground electronic music scene as well as an all-female DJ roster spinning hard-hitting EDM beats. Sunday Family & Furkids Carnival Family & Furkids Sunday (25 June) will transform the festival grounds to welcome families and pet owners, with a host of family-friendly activities that include: A games arena for children under 18 years-old Pet-friendly spaces for visitors to eat, drink and chill The return of the Annual Beerfest Blues and Rock Jam at the Malt Stage The Singapore Originals Artist Showcase featuring aspiring local artistes at the Hops Stage Launch Of Brewtopia Bangkok Constellar is partnering with Index Creative Village to launch Beerfest Asia's first overseas edition since the pandemic: Brewtopia Bangkok. The inaugural event will be the largest international craft & culture festival in Thailand with more than 300 brands of beverages, highlighting local brews and cuisine with the aim of making Thailand a must-visit craft and food destination for international and regional travellers. Brewtopia Bangkok will take place from 17 to 19 November at Sermsuk Warehouse along the scenic Chao Phraya river in Bangkok. Visit the Brewtopia Bangkok booth at Beerfest Asia 2023 for exclusive Super Early Bird Tickets for Brewtopia Bangkok and Travel - Stay and Brewtopia Ticket Package deals. Get Your Beerfest Asia 2023 Tickets Limited advanced tickets for Beerfest Asia 2023 are available for purchase until the event day; visitors can also purchase tickets on-site at the event. General admission ticket holders can select a complimentary welcome beer from a specially curated list of 17 brews, while VIP ticket holders will enjoy over 50 varieties of free-flow beer in the VIP Deck Bar. Beerfest Asia 2023 is proudly supported by Official Music Partner Jinro, Preferred Payment Partner UOB Evol, Official Water Partner Fiji Water, and Official Hotel Partner Hotel G. Get tickets and the latest updates on the Beerfest Asia website, and follow us on Facebook and Instagram About Beerfest Asia Beerfest Asia is co-owned by Constellar and lifestyle company Timbre Group. With a vision to become the largest beer festival in Southeast Asia, Beerfest is a tribute to the experimentation process of discovering and enjoying beers that consumers may not otherwise have come across locally. It is also the premier beer marketplace in Asia offering the industry a vibrant platform for to knowledge exchange, connections and product showcases. About Constellar Constellar connects a global eco-system of event partners and consumers through a holistic portfolio of intellectual property (IP) in the Meetings, Incentives, Conventions and Exhibitions (MICE) industry. As Asia's partner of reference for curating innovative event and venue experiences, Constellar activates impactful networks to bring global markets, businesses and consumers together for sustainable growth. With our expertise and dedication, we are invested in helping you build trusted relationships with stakeholders for the long term and enabling cross-industry collaboration through world-class audience engagement solutions. Visit constellar.co for more information.
新加坡2023年6月16日 /美通社/ -- 近日，美國法院就一起數位貨幣詐騙案作出了判決，此案涉及數月內進行數億美元的非法數位貨幣交易和「影子銀行」詐騙行為。與此同時，美東時間，2023年6月6日，美國證券交易委員會（SEC）也宣布超過19個數位貨幣為實際意義上的證券，後續將出台這些數位貨幣的相關立法。 因此，在美國法院與SEC針對數位貨幣相關法規的不斷督促與修正下， 此次詐騙事件再次凸顯了遵循法規和透明性在數位貨幣行業的重要性。 在這種情況下，Knnex重申其一直以來的承諾，那就是始終為Knnex的用戶提供安全，公正和完全符合規定的數位貨幣交易體驗。避免用戶遭受到數位貨幣詐騙事件的影響，Knnex相信透明性、合規性和用戶的信任是其數位貨幣交易業務的基石。 Knnex的專業法務團隊確保Knnex平台完全符合所有相關法律和規定，嚴格遵守美國聯邦與各國法律，不斷追求確保Knnex的操作和服務符合最新的法律要求。因為Knnex深知信任是與用戶建立長期關係的基石，所以Knnex始終與用戶保持透明溝通並提供訊息明確的資訊與公告，讓用戶明白Knnex如何處理他們的資產和保障他們的個人訊息安全。 各國針對數位貨幣行業的相關政策正在不斷變化，Knnex作為行業領先的數位貨幣交易所， 有責任與義務確保Knnex的用戶在不斷完善的法律法規下安全並自在的進行數位資產交易。 為了落實這個責任與義務，Knnex高度重視用戶的資產安全與平台的合規性，並試圖在這個快速變化且高度數位化的區塊鏈產業，建立一個穩定且安全的數位貨幣交易環境。以下是Knnex針對這類安全問題所實施的一些防範措施： 嚴格的用戶驗證：為了遵守KYC（Know Your Customer）和AML（Anti-Money Laundering）規定，Knnex對所有用戶進行嚴格的身分驗證。這包括驗證用戶的身分資料、聯絡方式以及地址等。 加密與安全存儲：Knnex對所有的數據進行加密處理，並且利用先進的安全技術和冷存儲方案，保護用戶的數位資產和個人資訊。 交易監控：Knnex使用先進的風險管理系統，以實時監控交易行為，從而及早發現並防止任何可疑或異常的交易。 法律合規：Knnex有專門的法律和合規部門，負責監督Knnex的業務操作，確保Knnex的服務符合各地區的法律法規。 用戶教育：Knnex相信知識是防範安全問題的關鍵，因此Knnex致力於提供豐富的教育資源，幫助用戶瞭解如何保護自己的資產並在Knnex的平台上進行安全交易。 透過以上這些措施，Knnex竭力為用戶提供一個安全、透明且公平的數位資產交易環境。未來，Knnex將繼續致力於創新並尋求新的方式來提升平台的安全性，以保護Knnex的用戶免於任何潛在的風險。 Knnex認識到在一個尚在蓬勃發展中的行業中，遵循相關法律法規的重要性與必要性。而Knnex將始終為確保數位貨幣交易的合法性、安全性和公平性而努力，並繼續致力於保護用戶的資產與資訊安全，遠離數位貨幣詐騙，與用戶一起探索區塊鏈技術的無窮可能。 Company: Knnex Group LimitedContact Person: KzEmail: support@knnexb.org Website: https://www.knnexb.org/City: Singapore
全球主權財富基金的資產管理規模在過去十年翻了一番 新加坡2023年6月19日 /美通社/ -- 全球領先的另類資產數據和洞察機構Preqin(睿勤)發佈了《2023年主權財富基金報告》。報告提供了關於主權財富基金領域關鍵趨勢的數據和分析，這類投資者希望加強另類資產的配置，並縮小實際配置與目標配置之間的差距。 報告顯示，如果另類資產能夠提供多元化收益和良好的風險調整後回報，那麼它們對主權財富基金的投資組合仍然很重要。主權財富基金擁有豐富的財政資源和日益成熟的投資團隊，其擁有的資本可以讓他們接觸到表現優異的基金。 關鍵事實： 資產管理規模(AUM)：在過去十年中，全球主權財富基金的AUM翻了一番，並在2023年第一季度末達到10.4萬億美元。 亞洲：亞洲的主權財富基金在AUM的增長方面處於領先地位，到2023年第一季度末達到4.3萬億美元。值得注意的是，中國投資有限責任公司(CIC)的AUM為1.35萬億美元，超過了挪威全球養老基金(Government Pension Fund Global)的1.2萬億美元，成為世界上規模最大的主權財富基金。 中東：中東是一些最大的主權財富基金的所在地，其AUM高達3.7萬億美元(占全球主權財富基金AUM的36%),位居全球第二，僅次於亞洲。 配置：2021年至2023年3月期間，除基礎設施外，主權財富基金對另類資產的配置占總配置的百分比在所有資產類別中都有所增長。目前配置中位數增加最多的是房地產，從2021年的6.5%攀升至2023年第一季度末的8.6%。 ESG：主權財富基金在促進環境、社會和治理(ESG)目標方面具有影響力。有ESG政策的主權財富基金占主權財富基金資產管理總額的59%，比2021年的54%上升了5個百分點。 報告的執行編輯和主要作者Harsha Narayan表示：「主權財富基金持續組建高端的內部團隊，在配置資本時越來越能夠像基金經理一樣行事。他們利用人才、技術和夥伴關係，與基金經理和投資者一起投資於各種另類資產，且越來越有能力進行直接或共同投資交易。」 媒體咨詢：Minty Ma（馬若冰）電郵：preqin.greaterchina@preqin.com
- Results from the largest European and first multicenter, retrospective, observational chart review study investigating the real-world use of ECP in heart transplant patients reinforce its use as a treatment for heart transplant rejection and prevention of rejection1 - DUBLIN, June 19, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced the publication of findings from a retrospective, observational, single arm, European chart review study assessing the real-world use of extracorporeal photopheresis (ECP) and its impact on clinical outcomes in the modern era of heart transplantation.1 An online version of the data manuscript – the largest-known study of ECP in heart transplant patients – is currently published on the Journal of Heart and Lung Transplantation website in advance of print publication in the second half of 2023. Interim results of this study were presented in a late-breaking session at the 20th Congress of the European Society for Organ Transplantation (ESOT) in 2021 in Milan, Italy.2 The study, titled "European Multicenter Study on The Real-World Use and Clinical Impact of Extracorporeal Photopheresis After Heart Transplantation," examined data from the medical charts of 105 patients who received ECP following heart transplantation at seven medical centers in Austria, Germany, France, Hungary, and Italy between 2015 – 2021. At time of data extraction, 58 patients (55.2%) had completed their ECP treatment and 47 patients' (44.8%) ECP treatment was ongoing.1 "These findings from the largest European and first multicenter study investigating the real-world use of ECP in heart transplant patients support ECP as a treatment for various types of graft rejection and in prevention of graft rejection with varied treatment schedules,1" said Markus Barten, M.D., Surgical Director of Heart Failure Clinic, University Heart and Vascular Center Hamburg. "This data not only builds upon the growing body of real-world evidence supporting the use of ECP in heart transplant patients, but also reflects the importance of supporting clinicians with treatment modalities for transplant rejection and stabilization.1" About the Study1 Mean age of patients at start of ECP was 47.7 (SD 14.4) years (min. 16 years to max. 74 years), and most patients (70.5%) were male. They were followed for a mean time of 25.1 (SD 16.8) months from ECP treatment initiation to last visit at the transplant center (follow-up time for outcome overall survival). Mean time from ECP treatment initiation to last visit right censored at 2 years after the end of ECP treatment was 22.5 (SD 13.7) months (follow-up time for outcomes graft function, response, and complications). Cardiomyopathy was the primary reason for heart transplantation (n=81 patients; 77.1%), followed by coronary heart disease (n=11 patients; 10.5%), heart valve disease (n=5 patients; 4.8%), and myocarditis (n=5 patients; 4.8%). The main reason to start ECP treatment was acute cellular rejection (ACR; n=37 patients; 35.2%), followed by prevention of rejection (n=34 patients; 32.4%), mixed rejection (n=19 patients; 18.1%), and antibody-mediated rejection (AMR; n=15 patients; 14.3%). The prevention of rejection subgroup included patients who started ECP treatment without biopsy-proven rejection and with standard or reduced immunosuppressive therapy. Key Findings1 Graft function was stable for almost all patients throughout the study who completed ECP and had graft function change assessed (97.2%; n=35/36). In patients who started ECP to treat ACR, AMR or mixed rejection (n=26), completed ECP treatment and had a biopsy at the start and end of treatment, 92.3% (n=24) were classified as responders, having demonstrated an improvement of ACR and/or AMR International Society for Heart and Lung Transplantation (ISHLT) grading after a mean ECP treatment duration of 5.4 months. The remaining patients had stable grades. In patients who started ECP to prevent rejection (n=34), 88.2% (n=30) remained free from any rejection over a mean follow-up of 26 months despite being considered at high risk for rejection and reduced immunosuppressive therapy. All patients started ECP treatment while on immunosuppressive therapy, and almost all remained on immunosuppressants until last reported visit prior to data extraction. Tacrolimus and mycophenolate derivatives were the most frequently used immunosuppressants. The number of patients on steroid therapy decreased slightly over time. Among patients with ongoing ECP treatment who remained on steroid therapy (n=34), steroid dose was reduced on average by 63.0% from start of ECP to last reported visit for 41.2% (n=14) of patients. Steroid dose increased for 5.9% (n=2) of patients and was stable in 52.9% (n=18) of patients. Among patients who completed ECP treatment and remained on steroid therapy (n=42), steroid dose was reduced on average by 67.0% from start of ECP to last reported visit for 52.4% (n=22) of patients. Steroid dose increased for 4.8% (n=2) of patients and was stable in 42.9% (n=18) of patients. Amongst the 19 patients in the prevention group, 16 (84.2%) received tacrolimus at the start of ECP and last reported visit. In 11/16 patients, tacrolimus trough levels were available of which 7 (63.6%) patients experienced an average trough level decrease of 34.0%. Amongst the 19 patients in the prevention group, 14 (70.4%) received mycophenolate derivatives at the start of ECP and last reported visit. In 4/14 patients, mycophenolate doses were available of which 100% of patients remained on stable mycophenolate derivate dose. Seventeen of 105 included patients (16.2%) experienced a complication after ECP treatment initiation, the most common of which was infections (n=13, 12.4%). Four of 105 patients (3.8%) experienced an endocrine/respiratory/blood/cardiac disorder, 2 patients (1.9%) an intolerance of high-dose immunosuppressive therapy, and 1 patient (1.0%) an acute kidney injury. Overall survival was 95.2% (n=100) over a mean follow-up of 25.1 (SD 16.8) months. Of the 5 deceased patients, 3 (60.0%) died with a functioning graft and 4 (80.0%) died after end of ECP treatment. No deaths were related to ECP. No major safety events occurred. Eighteen of 105 included patients (17.1%) had at least one ECP-related safety event, the most common of which was complications with venous access (n=13; 12.4%). Two (15.4%, n=2/13) patients stopped their ECP treatment as a result. Furthermore, 6/105 patients (5.7%) had ECP-related anemia, 3 patients (2.9%) ECP-related hypotension, 1 patient (1.0%) ECP-related fever, and 2 patients (1.9%) had an unspecified ECP-related safety event, but none of them discontinued their ECP treatment as a result. Limitations1 The effectiveness of ECP in comparison with other treatment options was not assessed due to the descriptive, single-arm design of this study. Study limitations include that data generation for this observational study was not standardized. Patient examination schedules varied and not all data were available at all centers. No source data verification was performed and therefore, transmission errors cannot be excluded. Not all demonstrated benefits may be solely attributable to ECP treatment, as transplanted patients may have received multiple therapies at time of ECP treatment. In patients with AMR or mixed rejection, ECP is commonly used in combination with other treatments. This study was funded by Mallinckrodt. IMPORTANT SAFETY INFORMATION FOR JAPAN Intended Use or EfficacyThis system is used as extracorporeal photopheresis therapy in steroid resistant or intolerant, chronic graft versus host disease. WarningsDirections for Use: When conducting extracorporeal photopheresis therapy for patients receiving other therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy. Taking into account the condition of the patient, administer an appropriate amount of anticoagulant through the CELLEX device, as thromboembolic events may occur. Contraindications / Prohibitions Directions for Use: Do not re-use (Procedural Kit and Methoxsalen Solution). Do not operate the instrument in the presence of flammable anesthetic gases, external radio or electromagnetic disturbances that may interfere with proper performance of the device. [There is the risk of ignition and malfunction.] Applicable subject (patient)Do not use for the following population. Patients who cannot tolerate extracorporeal volume loss. [Because the patient has possibility of hypotension and shock disease.] Patients exhibiting idiosyncratic reactions to psoralen compounds including methoxsalen, or possessing a specific history of a light-sensitive disease state. Patients with aphakia. [Because of the significantly increased risk of retinal damage due to the absence of a lens.] Patients possessing a specific history of a disordered coagulation or patients who have had previous splenectomy. [Anticoagulants is used during therapy.] Patients during pregnancy and lactation. [There is likely to cause harm to the unborn child or suckling infant.] Patients who have white blood cell counts greater than 25,000/mm3. [Design limit for sensor on instrument.] ABOUT THE THERAKOS CELLEX ECP SYSTEM FOR JAPAN The CELLEX System delivers extracorporeal photopheresis (ECP), and consists of an instrument, procedural kit, methoxsalen solution and a UVA lamp. The CELLEX System was designated as a medical device to be introduced early in Japan by the 15th Study Panel on Early Introduction of Highly Needed Medical Devices. This meeting was organized by the MHLW and held on February 17, 2011. CELLEX was also designated as an orphan medical device by the MHLW on January 18, 2017. APPROVED USES FOR THE THERAKOS CELLEX ECP SYSTEMThe approved uses for CELLEX ECP differ depending upon the country. Please refer to each country's Operator's manuals and labeling for approved uses. About Extracorporeal Photopheresis (ECP)ECP, a blood based immunomodulatory therapy developed more than 30 years ago, is recommended by the International Society for Heart and Lung Transplantation (ISHLT)3 and other clinical societies4,5,6 as an adjunctive therapy for the prevention and treatment of ACR after heart transplantation. Additionally, ECP may be considered to treat AMR with or without donor specific antibodies.7,8 In countries where it is approved, ECP is used to treat a range of immune-mediated diseases, including skin manifestations of cutaneous T-cell lymphoma (CTCL), graft-versus-host disease (GvHD), solid organ transplant rejection and other autoimmune diseases. During ECP treatment, a small amount of white blood cells is collected and treated with a drug that is activated by ultraviolet light. ABOUT MALLINCKRODT Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com. Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website. CAUTIONARY STATEMENTS RELATED TO FORWARD-LOOKING STATEMENTSThis release contains forward-looking statements, including with regard to ECP and its potential impact on patients. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; changes in laws and regulations; issues with product quality, manufacturing or supply, or patient safety issues; and other risks identified and described in more detail in the "Risk Factors" section of Mallinckrodt's most recent Annual Report on Form 10-K and other filings with the SEC, all of which are available on its website. The forward-looking statements made herein speak only as of the date hereof and Mallinckrodt does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law. CONTACT Media InquiriesHeather GuzziSenior Vice President, Green Room Communications973-524-4112hguzzi@grcomms.com Investor RelationsDaniel J. Speciale Global Corporate Controller & Chief Investor Relations Officer314-654-3638daniel.speciale@mnk.com Derek BelzVice President, Investor Relations314-654-3950derek.belz@mnk.com Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. ©2023 Mallinckrodt. JP-2300005 06/23 1 Barten, MJ et al. European multi-center study on the real-world use and clinical impact of extracorporeal photopheresis after heart transplantation. J Heart Lung Transplant. 2023. https://doi.org/10.1016/j.healun.2023.03.005.2 Barten, MJ. et al. Real World Use and Clinical Impact of Extracorporeal Photopheresis in Heart Transplant Patients – Results From a European Multi-Centre Study. Abstract presented at: European Society for Organ Transplantation (ESOT) Congress 2021. August/September 2021.3 Costanzo MR, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Trans. 2010:29(8);914–956.4 Alfred et al. The role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society. Br J Haematol. 2017;177(2):287-310.5 Padmanabhan et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019;34:171–354.6 Knobler et al. European dermatology forum - updated guidelines on the use of extracorporeal photopheresis 2020 - part 2. Eur Acad Dermatol Venereol. 2021;35(1):27-49.7 Colvin et al. Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2015;131(18):1608-1639.8 Barten et al. Transplant Rev (Orlando). The clinical impact of donor-specific antibodies in heart transplantation. 2018;32(4):207-217. Logo - https://mma.prnasia.com/media2/167103/mallinckrodt_plc_logo.jpg?p=medium600
- Professor Heungjeong Woo of Hallym University College of Medicine, announced the result of Xafty's clinical study at Emerging Science Session of the American Society for Microbiology (ASM) Microbe 2023 - Dr. Jo White evaluated Xafty's clinical results as "The birth of Penicillin of Antivirals" and "a groundbreaking achievement that suggests a solution to respiratory virus diseases" HOUSTON, June 18, 2023 /PRNewswire/ -- The result of clinical study for EUA (emergency use authorization) on COVID-19 with Xafty™ (CP-COV03) was presented at the 'Emerging Science' session of the American Society for Microbiology (ASM) Microbe 2023 conference, one of the largest conferences on infections and microbiology held in Houston, Texas, on June 17, 2023. Dr. Heungjeong Woo, a professor from Hallym University School of Medicine, South Korea, presented the meaning and expected effects from the study, a randomized double-blinded placebo-controlled trial with 300 patients combining phase 2 and 3. Xafty is a novel antiviral oral drug developed by Hyundai Bioscience (KOSDAQ 048410) of South Korea. Clinical And Virological Efficacy This clinical study demonstrated the following great key results: The blood concentration of the drug and the viral load showed a negative correlation. The viral load decreased by 4.1% in the placebo group 16 hours after the first dose, whereas the Xafty group's viral load decreased by 56.65% (p-value 0.0185). As a result, the time to improve twelve COVID-19 symptoms (fever, cough, sore throat, headache, etc.) was shortened by 4 days than that of the placebo group (p-value 0.0083). Particularly, in the high-risk group where existing medication was allowed (hyperlipidemia, hypertension, diabetes medicine, etc.) was found that the time to improve twelve COVID-19 symptoms was shortened by 6 days compared to the placebo group (p-value 0.0080). Niclosamide, the active pharmaceutical ingredient (API) of Xafty, has been found as effective against major viral infections (COVID-19, SARS, MERS, influenza, RSV, etc.) that cause respiratory infections by various in-vitro studies in the past decades. Since niclosamide is hard to be absorbed into the body, its effective blood concentration to inhibit viral replication cannot be maintained, making it difficult to be delivered to infected cells. With such problem not been solved, no significant progress was made in animal studies and clinical trials. Hyundai Bioscience overcame the challenge of niclosamide with its proprietary drug delivery technology using bio-compatible inorganic compound and polymer so that niclosamide is properly absorbed into the body and stays in the intestine for a prolonged time for slow release, enabling the effective antiviral concentration of niclosamide to be maintained for 5 days. The main target of the respiratory virus is the lung, where numerous blood vessels for oxygen supply exist. It was confirmed that Xafty delivers niclosamide well to the lung through the blood while maintaining an effective antiviral concentration. Hyundai Bioscience's animal testing demonstrated the concentration of niclosamide delivered to the lung was 2 to 10 times higher than in the blood. Professor Woo said that the clinical result of Xafty has three meanings. First, it made it possible to treat human viral infections by overcoming the problems (low absorption rate and short half-life) of niclosamide, which had been found to be effective in various viruses by in-vitro studies. Second, it was confirmed that, if niclosamide is found to be effective against the respiratory virus by in-vitro or animal tests, treating the viral infection in humans can also be achieved. Third, the viruses that has caused the pandemic so far are all respiratory and RNA viruses that cause endless mutations. Due to the nature of RNA viruses, it is impossible to develop a treatment for each individual virus. Xafty presented an innovative way to treat multiple respiratory viral infections with a single drug. More than half of viral infections are respiratory infections, and six families of viruses (Coronaviruses such as COVID-19, Orthomyxoviridae such as influenza, Paramyxoviridae, Picornaviridae, Adenoviridae, and Herpesviridae) are known to cause respiratory infections. Currently, there is no cure for respiratory viral infections other than COVID-19 and influenza and no drugs are discovered. In-vitro studies from 2004 to 2021 have discovered that niclosamide, the main pharmaceutical ingredient of Xafty, is effective against not only the six families of respiratory viruses, but also against the eight families of viruses (Coronavirus including COVID-19, SARS and MERS, Orthomyxovirus, Paramyxovirus, Picorna virus, Flavivirus, Buniya virus, Filovirus, and Alphavirus) that NIH and Bill & Melinda Gates Foundation decided to support the development of treatments for future pandemics.(U.S. Biden administration has decided to support $88.2 billion for 5 years to prepare for future pandemics.) Dr. Jo White, a viral disease expert with 35 years of experience in clinical research at pharmaceutical companies such as Merck and BMS, commented on the result of Xafty's clinical study, "With the advent of penicillin antibiotics, mankind had been freed from fear of bacterial pandemic. As such, the birth of Xafty, the 'penicillin' of antivirals, may be viewed as a groundbreaking achievement that presents a solution to respiratory viral infections in the future." [About Hyundai Bioscience] HYUNDAI BIOSCIENCE is a biotechnology company that develops drugs based on its novel drug delivery system technologies to deliver active ingredients safely and efficiently to targeted areas of the human body. Founded in 2000, Hyundai Bioscience focuses on repurposing or expanding indications of existing drugs using its proprietary organic-inorganic hybrid technologies. Hyundai Bioscience is a public company listed on the KOSDAQ (symbol: 048410) in South Korea. For more information, please contact:Mr. Joshua Kim, Managing Director, Hyundai Bioscience (planning@hyundaibio.com) Background Methods Conclusion
evoluSHEIN x Anitta Offers a Full-Size Range of Styles Featuring Sustainable Materials and Responsible Manufacturing LOS ANGELES, June 17, 2023 /PRNewswire/ -- SHEIN, a global e-retailer of fashion, beauty and lifestyle products, today announced it has teamed up with global pop star Anitta to launch evoluSHEIN x Anitta, the first product collaboration featured under SHEIN's evoluSHEIN by Design initiative, which has accelerated the use of more sustainable materials and responsible manufacturing practices company-wide. SHEIN is working to reduce the environmental impact of its products with the ambition to source a majority of SHEIN-branded products according to its evoluSHEIN by Design Standard by 2030, rewarding responsible suppliers and promoting awareness to its global following of fashion enthusiasts. "I am happy that SHEIN is taking an important step in sustainability and its overall environmental impact," said Anitta. "We all want to look great, while also respecting the planet and people." The new collection showcases the three key environmentally focused material programs SHEIN has launched in the past year: Styles made from recycled polyester support the transition away from virgin polyester and contribute to SHEIN's decarbonization strategy. Forest-safe viscose styles are part of SHEIN's commitment to source wood-derived fibers from suppliers that do not endanger vital ancient forests. Several limited-edition styles are made using rescued textiles left over by other fashion brands, creatively giving new purpose to high quality excess fabrics rather than letting them go to waste in landfill or incineration. Each piece is made according to the evoluSHEIN by Design Standard, which requires garments to consist of at least 30% preferred materials and be manufactured by suppliers that have achieved high social and environmental compliance verification through third-party audits. All items in the collection are shipped in packaging made with recycled content. "evoluSHEIN by Design supports a more circular system that mitigates textile waste and reduces consumption of new raw materials," said Caitrin Watson, Director of Sustainability at SHEIN. "We aim to continue reducing the environmental impact of our products while collaborating with other industry leaders to propel the circular textile economy forward. Launching this collection with Anitta is an opportunity to promote alternative and informed fashion choices in a way that is engaging for our customers and brings them along on our evoluSHEIN journey." As SHEIN continues to evolve its business with the vision of building a desirable fashion future accessible to all, evoluSHEIN by Design touches on many of the company's positive impact priorities. Among those priorities are responsible product sourcing, optimizing resource efficiency and opportunities for circularity, and improving lives in communities around the world. These ambitions, among others, are outlined in the evoluSHEIN Roadmap – SHEIN's holistic approach to addressing the most critical social and environmental challenges facing the fashion industry today. For more information on evoluSHEIN x Anitta, please visit shein.com. Follow along on social media with #evoluSHEINxANITTA — on Instagram @sheinofficial @shein_us and on TikTok @shein_official @shein_us. DOWNLOAD HIGH-RES IMAGES HERE of evoluSHEIN x ANITTA CAMPAIGN ABOUT SHEIN SHEIN is a global, integrated marketplace offering extended fashion and lifestyle shopping categories from SHEIN branded apparel to products from a global network of sellers, all at affordable prices. Headquartered in Singapore, SHEIN remains committed to making the beauty of fashion accessible to all, leveraging its industry-leading on-demand production methodology since 2012, for a smarter and more sustainable industry. Save money. Live in style! ABOUT ANITTA Since breaking through in Brazil six years ago, Grammy-nominated global superstar Anitta has become the leading artist of a new generation of Latin American music. As the biggest global female popstar to come from Brazil, she has amassed over 64 million Instagram followers and nearly 17 million YouTube subscribers, garnering more than 6 billion views. Anitta recently became a first time Grammy nominee in the "Best New Artist" category and has also been named among the world's 15th most influential musicians on social media by Billboard. MEDIA CONTACT: Maxine Silvamaxine.silva@sheingroup.com James TeJames.te@sheingroup.com
A12 藝術空間
Type-C
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
